Alpha Tau Medical is a clinical-stage company developing a radiation therapy that treats solid tumors by placing tiny alpha-emitting seeds inside the cancer. Think of it as a precision-guided radiation implant for hard-to-reach tumors.
No revenue yet; the company burns cash, with net losses of USD -0.04B in 2025 and USD -0.03B in 2024. Money comes only from investors, not operations, and margins are nonexistent.
Its Alpha DaRT technology is unique in delivering alpha radiation directly into tumors, a niche that competitors like Elekta and Varian (Siemens Healthineers) haven't replicated. But the moat is eroding as clinical trials face delays and the company's cash bur
Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
